Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Complement Profiles in Patients with Amyotrophic Lateral Sclerosis: A Prospective Observational Cohort Study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{f916653ecd0c48c285386e9489381af4,
title = "Complement Profiles in Patients with Amyotrophic Lateral Sclerosis: A Prospective Observational Cohort Study",
abstract = "Background: The complement system has been suggested to be involved in the pathophysiology of amyotrophic lateral sclerosis (ALS), a progressive motor neuron disease. In the present study, we compared levels of selected complement markers to clinical outcome in ALS patients.Methods: This observational, explorative cohort study included 92 ALS patients, 61 neurological controls (NCs) admitted for suspected aneurysmal subarachnoid haemorrhage, and 96 neurologically healthy controls (NHCs). Peripheral blood and cerebrospinal fluid (CSF) were obtained for the measurement of ficolin-1, -2, and -3; collectin-11, MBL, MASP-3, MAP-1, C4, C3, PTX-3, and complement activation products C4c, C3bc, and sC5b-9. We recorded clinical outcomes of ALS patients for 24 to 48 months after inclusion in order to analyse the effects of the complement markers on survival time.Results: Compared with both control groups, ALS patients exhibited increased collectin-11, C4 and sC5b-9 in plasma, as well as increased ficolin-3 in CSF. Ficolin-2 was significantly decreased in plasma of the ALS patients compared with NHCs, but not with NCs. The concentration of collectin-11, C3 and C3bc correlated negatively with the revised ALS functional rating scale (ALSFRS-R). No association was found between levels of complement markers and survival as estimated by hazard ratios.Conclusion: ALS patients exhibit aberrant expression of selected mediators of the lectin complement pathway as well as increased activation of the terminal complement pathway, corroborating the notion that the complement system might be involved in the pathophysiology of ALS.",
keywords = "Amyotrophic lateral sclerosis, Cerebrospinal fluid, Complement, Innate immunity, Lectin pathway, Observational cohort study, Pathophysiology",
author = "Anne-Lene Kj{\ae}ldgaard and Katrine Pilely and Olsen, {Karsten Skovgaard} and {{\O}berg Lauritsen}, Anne and {W{\o}rlich Pedersen}, Stephen and Kirsten Svenstrup and Merete Karlsborg and Helle Thagesen and Morten Blaabjerg and {\'A}sta The{\'o}d{\'o}rsd{\'o}ttir and {Gundtoft Elmo}, Elisabeth and {Torvin M{\o}ller}, Anette and Pedersen, {Niels Anker} and Niels Kirkegaard and Kirsten M{\o}ller and Peter Garred",
note = "{\textcopyright} 2021 Kj{\ae}ldgaard et al.",
year = "2021",
doi = "10.2147/JIR.S298307",
language = "English",
volume = "14",
pages = "1043--1053",
journal = "Journal of Inflammation Research",
issn = "1178-7031",
publisher = "Dove Medical Press Ltd",

}

RIS

TY - JOUR

T1 - Complement Profiles in Patients with Amyotrophic Lateral Sclerosis

T2 - A Prospective Observational Cohort Study

AU - Kjældgaard, Anne-Lene

AU - Pilely, Katrine

AU - Olsen, Karsten Skovgaard

AU - Øberg Lauritsen, Anne

AU - Wørlich Pedersen, Stephen

AU - Svenstrup, Kirsten

AU - Karlsborg, Merete

AU - Thagesen, Helle

AU - Blaabjerg, Morten

AU - Theódórsdóttir, Ásta

AU - Gundtoft Elmo, Elisabeth

AU - Torvin Møller, Anette

AU - Pedersen, Niels Anker

AU - Kirkegaard, Niels

AU - Møller, Kirsten

AU - Garred, Peter

N1 - © 2021 Kjældgaard et al.

PY - 2021

Y1 - 2021

N2 - Background: The complement system has been suggested to be involved in the pathophysiology of amyotrophic lateral sclerosis (ALS), a progressive motor neuron disease. In the present study, we compared levels of selected complement markers to clinical outcome in ALS patients.Methods: This observational, explorative cohort study included 92 ALS patients, 61 neurological controls (NCs) admitted for suspected aneurysmal subarachnoid haemorrhage, and 96 neurologically healthy controls (NHCs). Peripheral blood and cerebrospinal fluid (CSF) were obtained for the measurement of ficolin-1, -2, and -3; collectin-11, MBL, MASP-3, MAP-1, C4, C3, PTX-3, and complement activation products C4c, C3bc, and sC5b-9. We recorded clinical outcomes of ALS patients for 24 to 48 months after inclusion in order to analyse the effects of the complement markers on survival time.Results: Compared with both control groups, ALS patients exhibited increased collectin-11, C4 and sC5b-9 in plasma, as well as increased ficolin-3 in CSF. Ficolin-2 was significantly decreased in plasma of the ALS patients compared with NHCs, but not with NCs. The concentration of collectin-11, C3 and C3bc correlated negatively with the revised ALS functional rating scale (ALSFRS-R). No association was found between levels of complement markers and survival as estimated by hazard ratios.Conclusion: ALS patients exhibit aberrant expression of selected mediators of the lectin complement pathway as well as increased activation of the terminal complement pathway, corroborating the notion that the complement system might be involved in the pathophysiology of ALS.

AB - Background: The complement system has been suggested to be involved in the pathophysiology of amyotrophic lateral sclerosis (ALS), a progressive motor neuron disease. In the present study, we compared levels of selected complement markers to clinical outcome in ALS patients.Methods: This observational, explorative cohort study included 92 ALS patients, 61 neurological controls (NCs) admitted for suspected aneurysmal subarachnoid haemorrhage, and 96 neurologically healthy controls (NHCs). Peripheral blood and cerebrospinal fluid (CSF) were obtained for the measurement of ficolin-1, -2, and -3; collectin-11, MBL, MASP-3, MAP-1, C4, C3, PTX-3, and complement activation products C4c, C3bc, and sC5b-9. We recorded clinical outcomes of ALS patients for 24 to 48 months after inclusion in order to analyse the effects of the complement markers on survival time.Results: Compared with both control groups, ALS patients exhibited increased collectin-11, C4 and sC5b-9 in plasma, as well as increased ficolin-3 in CSF. Ficolin-2 was significantly decreased in plasma of the ALS patients compared with NHCs, but not with NCs. The concentration of collectin-11, C3 and C3bc correlated negatively with the revised ALS functional rating scale (ALSFRS-R). No association was found between levels of complement markers and survival as estimated by hazard ratios.Conclusion: ALS patients exhibit aberrant expression of selected mediators of the lectin complement pathway as well as increased activation of the terminal complement pathway, corroborating the notion that the complement system might be involved in the pathophysiology of ALS.

KW - Amyotrophic lateral sclerosis

KW - Cerebrospinal fluid

KW - Complement

KW - Innate immunity

KW - Lectin pathway

KW - Observational cohort study

KW - Pathophysiology

UR - http://www.scopus.com/inward/record.url?scp=85103112377&partnerID=8YFLogxK

U2 - 10.2147/JIR.S298307

DO - 10.2147/JIR.S298307

M3 - Journal article

C2 - 33790619

VL - 14

SP - 1043

EP - 1053

JO - Journal of Inflammation Research

JF - Journal of Inflammation Research

SN - 1178-7031

ER -

ID: 64825784